A Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia is a PHASE1 clinical asset sponsored by Bioray Laboratories in Beta-Thalassemia. SEO and diligence focus: BRL-101, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.